Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bicycle Therapeutics plc - American Depositary Shares
(NQ:
BCYC
)
7.420
+0.010 (+0.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bicycle Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
Next >
Why Shares of Bicycle Therapeutics Were Rising on Monday
September 11, 2023
The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.
Via
The Motley Fool
Exposures
Product Safety
Where Bicycle Therapeutics Stands With Analysts
September 07, 2023
Via
Benzinga
Expert Ratings for Bicycle Therapeutics
August 04, 2023
Via
Benzinga
Why Bicycle Therapeutics Stock Raced Ahead Today
July 13, 2023
The company's latest attempt at capital raising seems to be having enviable success.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
July 13, 2023
Via
Benzinga
Stratasys, MillerKnoll, Nikola And Other Big Stocks Moving Higher On Thursday
July 13, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. Nikola Corporation (NASDAQ: NKLA) gained 18% to...
Via
Benzinga
Bicycle Therapeutics's Return On Capital Employed Insights
May 17, 2023
Via
Benzinga
14 Analysts Have This to Say About Bicycle Therapeutics
May 11, 2023
Via
Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Analyst Ratings for Bicycle Therapeutics
April 18, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Bicycle Therapeutics
March 01, 2023
Via
Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022
August 31, 2022
Upgrades
Via
Benzinga
Expert Ratings for Bicycle Therapeutics
August 22, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Bicycle Therapeutics
May 23, 2022
Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Expert Ratings for Bicycle Therapeutics
May 06, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
November 23, 2022
Via
Benzinga
Recap: Bicycle Therapeutics Q3 Earnings
November 03, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Looking Into Bicycle Therapeutics's Return On Capital Employed
August 22, 2022
According to data from Benzinga Pro, during Q2, Bicycle Therapeutics's (NASDAQ:BCYC) reported sales totaled $4.38 million. Despite a 2.67% increase in earnings, the company posted a loss of $26.83...
Via
Benzinga
Bicycle Therapeutics: Q2 Earnings Insights
August 04, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
Recap: Bicycle Therapeutics Q1 Earnings
May 05, 2022
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Where Bicycle Therapeutics Stands With Analysts
April 13, 2022
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:
Via
Benzinga
Where Bicycle Therapeutics Stands With Analysts
July 06, 2022
Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 24, 2022
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of their outstanding shares is at $47.6 million. As per the press...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
June 06, 2022
Monday's session saw 84 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
During Friday's session, 59 stocks hit new 52-week lows.
Via
Benzinga
Bicycle Therapeutics's Return On Capital Employed Overview
May 27, 2022
Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from last quarter.
Via
Benzinga
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
April 13, 2022
B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics...
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.